HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Semen quality in patients with Chlamydia trachomatis genital infection treated concurrently with prulifloxacin and a phytotherapeutic agent.

Abstract
Chronic prostatitis (CP) due to Chlamydia trachomatis (Ct) infection has a significant impact on young male fertility, and eradication of Ct infection after antibiotic therapy does not always result in recovery of semen quality. The study aim was to evaluate the effects on fertility parameters of L-arginine, L-carnitine, acetyl-L-carnitine, and ginseng extracts (FERTIMEV) associated with prulifloxacin in patients affected by CP and oligoasthenoteratozoospermia due to Ct infection. Two hundred and six patients with proven Ct genital infection and oligoasthenoteratozoospermia were enrolled in a prospective, randomized, and controlled study. Prulifloxacin (600 mg) was administered daily for 14 days, and patients were divided into 2 groups: group A: antibiotic therapy alone; and group B: antibiotic therapy and additional therapy with FERTIMEV (1 vial daily for 6 months). Microbiological and semen parameter analyses were performed both at enrollment and after 6 months. National Institutes of Health Chronic Prostatitis Symptom Index and International Prostatic Symptom Score questionnaires were applied. Of the 206 patients, 109 were assigned to group A and 97 to group B. At the enrollment time, no differences were reported with regard to clinical, instrumental, and laboratory data. Six months after treatment, statistically significant differences were demonstrated between both groups in terms of sperm concentration (21.3 ± 13.2 millions/mL vs 11.5 ± 13.2 millions/mL) (Cohen's d = 0.61) (P < .001, df = 2, F = 62.10) and percentage of motile sperm (42.4% ± 5.2% vs 29.3% ± 11.0%) (Cohen's d = 1.52) (P < .001, df = 2, F = 91.48). In this study treatment with FERTIMEV together with prulifloxacin improved semen parameters in patients with Ct genital infection and oligoasthenoteratozoospermia compared to treatment with prulifloxacin therapy alone.
AuthorsTommaso Cai, Florian M E Wagenlehner, Sandra Mazzoli, Francesca Meacci, Nicola Mondaini, Gabriella Nesi, Daniele Tiscione, Gianni Malossini, Riccardo Bartoletti
JournalJournal of andrology (J Androl) 2012 Jul-Aug Vol. 33 Issue 4 Pg. 615-23 ISSN: 1939-4640 [Electronic] United States
PMID21979301 (Publication Type: Journal Article, Randomized Controlled Trial)
Chemical References
  • Dioxolanes
  • Fluoroquinolones
  • Piperazines
  • Plant Extracts
  • Acetylcarnitine
  • Arginine
  • prulifloxacin
  • Carnitine
Topics
  • Acetylcarnitine (administration & dosage)
  • Adult
  • Arginine (administration & dosage)
  • Asthenozoospermia (drug therapy)
  • Carnitine (administration & dosage)
  • Chlamydia Infections (drug therapy)
  • Chlamydia trachomatis
  • Dioxolanes (administration & dosage)
  • Fluoroquinolones (administration & dosage)
  • Humans
  • Male
  • Oligospermia (drug therapy)
  • Panax (chemistry)
  • Piperazines (administration & dosage)
  • Plant Extracts (administration & dosage)
  • Prostatitis (drug therapy)
  • Semen Analysis

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: